Akari Therapeutics
IPOPublic · London, United Kingdom · Founded 2012 · $14.6M raised
- Headquarters
- London, Massachusetts
- Employees
- 1–10
- Founded
- 2012
- Business Model
- B2B
- Website
- akaritx.com
- Total Funding
- $14.6M
- Last Round
- $5.0M Venture RoundDec 2025
- Rounds
- 3
- Type
- Public
About
Akari Therapeutics is a clinical-stage oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) with a novel spliceosome-targeting payload (PH1). The company's lead program, AKTX-101, is advancing toward a Phase 1 first-in-human clinical trial. Akari is listed on Nasdaq (AKTX) and operates from New York and Boston.
Summary
Akari Therapeutics is an Antibody-Drug Conjugates company based in London, United Kingdom, founded in 2012. It has raised $14.6M in total across 3 rounds, most recently a $5.0M Venture Round round in Dec 2025.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Clinical-stage precision medicines company using protein-motion-driven drug discovery to design s...
Biotechnology company that discovers and develops medicines for serious, life-threatening disease...